Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398885 | 0.89 | NPBWR1 (0.45) | MAPTNPBWR1PDE5AKMT2ACYP3A4 | |
| SCHEMBL5405288 | 0.86 | SLC16A1 (0.47) | TSHRMAPTTP53PDE5AKMT2A | |
| SCHEMBL5404511 | 0.84 | NPBWR1 (0.40) | XIAPTSHRMAPTNPBWR1PDE5A | |
| SCHEMBL5395967 | 0.81 | NPBWR1 (0.41) | MAPTNPBWR1PDE5AKMT2ACYP3A4 | |
| SCHEMBL5405558 | 0.81 | SLC16A1 (0.47) | MAPTTP53CYP3A4CYP2C9SLC16A1 | |
| SCHEMBL5407983 | 0.80 | NPBWR1 (0.42) | XIAPMAPTNPBWR1PDE5AKMT2A | |
| SCHEMBL5400652 | 0.80 | MAPT (0.48) | MAPTTP53SLC16A1 | |
| SCHEMBL5405716 | 0.80 | TP53 (0.44) | TSHRMAPTTP53SLC16A1 | |
| SCHEMBL6656130 | 0.79 | PDE5A (0.41) | TSHRMAPTNPBWR1PDE5ACYP3A4 | |
| SCHEMBL5403865 | 0.79 | PDE5A (0.45) | NPBWR1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | XIAP 2167/4885TSHR 3317/4885MAPT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.